|
|||||
|
|
| 骨髓增殖性肿瘤治疗进展:第56届美国血液学会年会报道 | |
| 引用本文： | 张陆阳,张丹凤,潘崚. 骨髓增殖性肿瘤治疗进展:第56届美国血液学会年会报道[J]. 白血病．淋巴瘤, 2015, 24(4). DOI: 10.3760/cma.j.issn.1009-9921.2015.04.001 |
| 作者姓名： | 张陆阳 张丹凤 潘崚 |
| 作者单位： | 四川大学华西医院血液科, 成都,610041 |
| 摘 要： | 近年对bcr-abl阴性的骨髓增殖性肿瘤的发病机制、诊断、风险分层及治疗等方面的研究取得了长足进展,文章就2014年第56届美国血液学会(ASH)年会上关于bcr-abl阴性的骨髓增殖性肿瘤治疗进展等内容作一介绍. |
| 关 键 词： | 骨髓增殖性肿瘤 羟基脲 干扰素 JAK抑制剂 靶向治疗 美国血液学会年会 |
Treatment advances in myeloproliferative neoplasms: reports from the 56th American Society of Hematology annual meeting |
|
| Zhang Luyang,Zhang Danfeng,Pan Ling. Treatment advances in myeloproliferative neoplasms: reports from the 56th American Society of Hematology annual meeting[J]. Journal of Leukemia & Lymphoma, 2015, 24(4). DOI: 10.3760/cma.j.issn.1009-9921.2015.04.001 | |
| Authors: | Zhang Luyang Zhang Danfeng Pan Ling |
| Abstract: | Great advances have been made in understanding the pathogenesis,diagnosis,risk stratification and treatment of classic bcr-abl-negative myeloproliferative neoplasms (MPN).This article reviews current situation in the treatment of these MPNs presented in the 56th American Society of Hematology (ASH) annual meeting. |
| Keywords: | Myeloproliferative neoplasm Hydroxycarbamide Interferon JAK inhibitors Targeted treatment American Society of Hematology annual meeting |
| 本文献已被 万方数据 等数据库收录！ | |